AI Verdict
NYT has stronger fundamentals based on our AI analysis.
NYT vs NXTC Fundamental Comparison
| Metric | NYT | NXTC |
|---|---|---|
| Revenue | $2.8B | $22.4M |
| Net Income | $344.0M | $-55.8M |
| Net Margin | 12.2% | -249.5% |
| ROE | 16.9% | -159.8% |
| ROA | 11.5% | -111.3% |
| Current Ratio | 1.54x | 4.14x |
| Debt/Equity | 0.12x | 0.00x |
| EPS | $2.09 | $-19.65 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
NYT vs NXTC: Frequently Asked Questions
Is NYT or NXTC a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), NYT has stronger fundamentals. NYT is rated BUY (72% confidence) while NXTC is rated SELL (78% confidence). This is not investment advice.
How does NYT compare to NXTC fundamentally?
NEW YORK TIMES CO has ROE of 16.9% vs NextCure, Inc.'s -159.8%. Net margins are 12.2% vs -249.5% respectively.
Which stock pays higher dividends, NYT or NXTC?
NYT has a dividend yield of N/A or no dividend while NXTC has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in NYT or NXTC for long term?
For long-term investing, consider that NYT has BUY rating with 72% confidence, while NXTC has SELL rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about NYT vs NXTC?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For NYT vs NXTC, the AI consensus favors NYT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.